DANVERS, Mass., April 13, 2018 -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, May 3, 2018, the Company will release financial results for the fourth quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, May 3, 2018, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. ET May 3, 2018 through 11:00 a.m. ET on May 10, 2018. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 448 8806.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information, please contact:
Ingrid Goldberg
Director, Investor Relations
978-646-1590
[email protected]


Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
How Marco Pharma International Preserves German Homeopathic Traditions in America
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 



